依特卡肽与马沙骨化醇对继发性甲状旁腺功能亢进患者血清钙化倾向的比较:一项随机临床试验
该随机对照试验在血液透析合并继发性甲状旁腺功能亢进患者中比较依特卡肽与马沙骨化醇对血清钙化倾向(T50值)的影响。12个月时,依特卡肽组T50值增加幅度显著大于马沙骨化醇组(差值20分钟,95%CI 7-34,P=0.004)。两组握力和认知评分变化无显著差异。
要点
- 依特卡肽较马沙骨化醇更显著提高血透患者T50值。
- T50值增加组间差值20分钟(95%CI 7-34,P=0.004)。
- 两组握力和认知评分变化无显著差异。
核心结论
- 在血液透析合并继发性甲状旁腺功能亢进患者中,依特卡肽较马沙骨化醇更有效提高T50值。
- 两药对握力和认知的影响无差异。
研究设计与样本
- 随机、多中心、开放标签、盲法终点、活性对照试验,在日本23个透析中心进行。
- 筛查425例,随机326例(依特卡肽组167例,对照组159例),意向性分析纳入321例,中位年龄66岁,女性113例(35%)。
主要发现
- 马沙骨化醇组T50值中位数(IQR)从116分钟(90-151)变为131分钟(102-176)。
- 依特卡肽组T50值中位数(IQR)从123分钟(98-174)变为166分钟(127-218)。
- T50值增加幅度组间差异为20分钟(95%CI 7-34,P=0.004),依特卡肽组更大。
- 握力和认知评分变化组间无显著差异。
关键数值与推荐
- 依特卡肽用法:静脉注射5 mg,每周三次。
- 马沙骨化醇用法:静脉注射5或10 µg,每周三次。
- 主要终点为基线至12个月T50值变化。
临床怎么用
- 对于血透合并继发性甲状旁腺功能亢进患者,若以改善钙化倾向为目标,可优先考虑依特卡肽。
- 需注意两药对握力和认知功能的影响无差异。
局限性
- 开放标签设计,可能引入偏倚。
- 仅纳入日本血透患者,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Vitamin D receptor activators and calcimimetics (calcium-sensing receptor agonists) are two major options for medical treatment of secondary hyperparathyroidism. A higher serum calcification propensity (a shorter T50 value) is a novel surrogate marker of calcification stress and mortality in patients with CKD. We tested a hypothesis that a calcimimetic agent etelcalcetide is more effective in increasing T50 value than a vitamin D receptor activator maxacalcitol. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A randomized, multicenter, open-label, blinded end point trial with active control was conducted in patients with secondary hyperparathyroidism undergoing hemodialysis in Japan. Patients were randomly assigned to receive intravenous etelcalcetide 5 mg thrice weekly (etelcalcetide group) or intravenous maxacalcitol 5 or 10 µg thrice weekly (maxacalcitol group). The primary, secondary, and tertiary outcomes were changes in T50 value, handgrip strength, and score of the Dementia Assessment Sheet for Community-Based Integrated Care System from baseline to 12 months, respectively. RESULTS: In total, 425 patients from 23 dialysis centers were screened for eligibility, 326 patients were randomized (etelcalcetide, n=167; control, n=159), and 321 were included in the intention-to-treat analysis (median age, 66 years; 113 women [35%]). The median (interquartile range) of T50 value was changed from 116 minutes (interquartile range, 90-151) to 131 minutes (interquartile range, 102-176) in the maxacalcitol group, whereas it was changed from 123 minutes (interquartile range, 98-174) to 166 minutes (interquartile range, 127-218) in the etelcalcetide group. The increase in T50 value was significantly greater in the etelcalcetide group (difference in change, 20 minutes; 95% confidence interval, 7 to 34 minutes; P=0.004). No significant between-group difference was found in the change in handgrip strength or in the Dementia Assessment Sheet for Community-Based Integrated Care System score. CONCLUSIONS: Etelcalcetide was more effective in increasing T50 value than maxacalcitol among patients on hemodialysis with secondary hyperparathyroidism. There was no difference in handgrip strength or cognition between the two drugs. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: VICTORY; UMIN000030636 and jRCTs051180156.
引用
- Shoji T, Nakatani S, Kabata D, et al. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial. Clin J Am Soc Nephrol. 2021. PMID: 33685864. doi:10.2215/CJN.16601020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。